medigraphic.com
SPANISH

Medicina Interna de México

Colegio de Medicina Interna de México.
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2021, Number 6

<< Back Next >>

Med Int Mex 2021; 37 (6)

Acute osteolysis following hypercalcemia of malignancy

Andrade-Castellanos CA, Novas-Rojas Y, Gutiérrez-Ramírez FJ
Full text How to cite this article

Language: Spanish
References: 9
Page: 1103-1107
PDF size: 205.49 Kb.


Key words:

Osteolysis, Hypercalcemia, Carcinoma.

ABSTRACT

Background: Acute hypercalcemia is a life-threatening condition that most commonly results from malignancy. Local osteolytic hypercalcemia (the local destruction of bone by tumor with calcium release) accounts for about 20% of cancer-related hypercalcemia. Destruction of bone by metastatic cancer is a late event, starting when tumor cells proliferate. Symptoms and complications of bone metastases (pain, pathologic fractures, compression of the spinal cord) become more evident as the disease becomes more extensive.
Clinical case: A 27-year-old female patient that developed acute osteolysis following hypercalcemia of malignancy.
Conclusions: What makes the present case unique was the rapid evolution of osteolysis during the hypercalcemic crisis, evidenced by computed tomography, in a temporality of only 14 days.


REFERENCES

  1. Aibek E, Mirrakhimov. Hypercalcemia of malignancy: An update on pathogenesis and management. N Am J Med Sci 2015; 7: 483-93. doi: 10.4103/1947-2714.170600.

  2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s. doi: 10.1158/1078-0432.CCR-06-0931

  3. Sisay M, Mengistu G, Edessa D. The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther 2017; 10: 3801-3810. doi: 10.2147/OTT.S135867.

  4. Sambandam Y, Ethiraj P, Hathaway-Schrader JD, Novince CM, et al. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells. J Cell Physiol 2018; 233 (8): 6125-6134. doi: 10.1002/jcp.26456.

  5. Liu S, Liu L, Ye W, Ye D, et al. High vimentin expression associated with lymph node metastasis and predicated a poor prognosis in oral squamous cell carcinoma. Sci Rep 2016; 6: 38834. doi: 10.1038/srep38834.

  6. Clézardin P. Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine 2017; 84 (6): 677-684. doi: 10.1016/j.jbspin.2017.05.006.

  7. Gallegos-Hernández JF. El cáncer de cabeza y cuello. Factores de riesgo y prevención. Cir Cir 2006; 74 (4): 287-293.

  8. Álvarez-Marcos CA, Fernández-Espina H, Llorente-Pendás JL, Franco-Gutiérrez V, et al. Metástasis a distancia en el cáncer de cabeza y cuello. Acta Otorrinolaringol Esp 2006; 57: 369-372. DOI: 10.1016/S0001-6519(06)78730-1.

  9. Grisanti S, Bianchi S, Locati LD, Triggiani L, et al. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS One 2019; 14 (3): e0213934. https://doi.org/10.1371/journal. pone.0213934.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Med Int Mex. 2021;37